デフォルト表紙
市場調査レポート
商品コード
1036688

濾胞性リンパ腫治療薬の世界市場:規模・現状・予測 (2021年~2027年)

Global Follicular Lymphoma Drugs Market Size, Status and Forecast 2021-2027

出版日: | 発行: QYResearch | ページ情報: 英文 109 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
濾胞性リンパ腫治療薬の世界市場:規模・現状・予測 (2021年~2027年)
出版日: 2021年11月11日
発行: QYResearch
ページ情報: 英文 109 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の濾胞性リンパ腫治療薬の市場規模は、2020年の16億1,600万米ドルから2027年には26億2,010万米ドルに達すると予測されています。

また、2021年から2027年の間に7.4%のCAGRで成長すると考えられています。

当レポートでは、世界の濾胞性リンパ腫治療薬の市場について分析し、種類別・投与経路別・地域別の市場動向の見通し (2016年~2027年)、主要企業のプロファイルなどについて調査しております。

目次

第1章 分析概要

  • 分析範囲
  • 種類別の市場分析
    • 市場規模・成長率:種類別 (2016年/2021年/2027年)
    • 抗CD20モノクローナル抗体
    • 化学療法剤
    • キナーゼ阻害剤
    • その他
  • 投与経路別の市場
    • 市場シェア:投与経路別 (2016年/2021年/2027年)
    • 注射剤
    • 経口剤
  • 分析対象
  • 分析期間

第2章 世界市場の成長動向

  • 世界の濾胞性リンパ腫治療薬市場:将来展望 (2016年~2027年)
  • 地域別の成長動向
    • 市場規模:地域別 (2016年/2021年/2027年)
    • 市場規模・シェア、実績値:地域別 (2016年~2021年)
    • 市場規模、予測値:地域別 (2022年~2027年)
  • 濾胞性リンパ腫治療薬産業の力学
    • 濾胞性リンパ腫治療薬市場の動向
    • 濾胞性リンパ腫治療薬市場の促進要因
    • 濾胞性リンパ腫治療薬市場の課題
    • 濾胞性リンパ腫治療薬市場の抑制要因

第3章 主要企業間の競合情勢

  • 大手企業の収益動向
    • 収益額:企業別 (2016年~2021年)
    • 収益額シェア:企業別 (2016年~2021年)
  • 市場シェア:企業の種類別 (ティア1、ティア2、ティア3)
  • 分析対象企業:収益額ランキング
  • 市場集中度
    • 市場集中度 (CR5、HHI)
    • 上位企業10社・5社の収益額 (2020年)
  • 主要企業の本社所在地・販売エリア
  • 主要企業の製品・ソリューション・サービス
  • 市場参入時期
  • 企業合併・買収 (M&A)/事業拡張計画

第4章 種類別の詳細データ

  • 市場規模、実績値:種類別 (2016年~2021年)
  • 市場規模、予測値:種類別 (2022年~2027年)

第5章 投与経路別の詳細データ

  • 市場規模、実績値:投与経路別 (2016年~2021年)
  • 市場規模、予測値:投与経路別 (2022年~2027年)

第6章 北米

  • 北米の市場規模 (2016年~2027年)
  • 種類別の市場規模
    • 市場規模、実績値:種類別 (2016年~2021年)
    • 市場規模、予測値:種類別 (2022年~2027年)
    • 市場規模:種類別 (2016年~2027年)
  • 投与経路別の市場規模
    • 市場規模、実績値:投与経路別 (2016年~2021年)
    • 市場規模、予測値:投与経路別 (2022年~2027年)
    • 市場規模:投与経路別 (2016年~2027年)
  • 国別の市場規模
    • 市場規模、実績値:国別 (2016年~2021年)
    • 市場規模、予測値:国別 (2022年~2027年)
    • 米国
    • カナダ

第7章 欧州

  • 欧州の市場規模 (2016年~2027年)
  • 種類別の市場規模
  • 投与経路別の市場規模
  • 国別の市場規模
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • 北欧諸国

第8章 アジア太平洋

  • アジア太平洋の市場規模 (2016年~2027年)
  • 種類別の市場規模
  • 投与経路別の市場規模
  • 国別の市場規模
    • 中国
    • 日本
    • 韓国
    • 東南アジア
    • インド
    • オーストラリア

第9章 ラテンアメリカ

  • ラテンアメリカの市場規模 (2016年~2027年)
  • 種類別の市場規模
  • 投与経路別の市場規模
  • 国別の市場規模
    • メキシコ
    • ブラジル

第10章 中東・アフリカ

  • 中東・アフリカの市場規模 (2016年~2027年)
  • 種類別の市場規模
  • 投与経路別の市場規模
  • 国別の市場規模
    • トルコ
    • サウジアラビア
    • アラブ首長国連邦

第11章 主要企業のプロファイル

  • Roche
  • Gilead Sciences
  • TG Therapeutics
  • Bayer
  • Secura Bio
  • Epizyme
  • Eisai
  • Acrotech Biopharma
  • Teva
  • Eagle Pharmaceuticals
  • MundiPharma

第12章 アナリストの視点/結論

第13章 付録

図表

List of Tables

List of Tables

  • Table 1. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
  • Table 2. Key Players of Anti-CD20 mAbs
  • Table 3. Key Players of Chemotherapy Agents
  • Table 4. Key Players of Kinase Inhibitor
  • Table 5. Key Players of Others
  • Table 6. Global Follicular Lymphoma Drugs Market Size Growth by Administration Route (US$ Million): 2016 VS 2021 VS 2027
  • Table 7. Global Follicular Lymphoma Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
  • Table 8. Global Follicular Lymphoma Drugs Market Size by Regions (2016-2021) & (US$ Million)
  • Table 9. Global Follicular Lymphoma Drugs Market Share by Regions (2016-2021)
  • Table 10. Global Follicular Lymphoma Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
  • Table 11. Global Follicular Lymphoma Drugs Market Share by Regions (2022-2027)
  • Table 12. Follicular Lymphoma Drugs Market Trends
  • Table 13. Follicular Lymphoma Drugs Market Drivers
  • Table 14. Follicular Lymphoma Drugs Market Challenges
  • Table 15. Follicular Lymphoma Drugs Market Restraints
  • Table 16. Global Follicular Lymphoma Drugs Revenue by Players (2016-2021) & (US$ Million)
  • Table 17. Global Follicular Lymphoma Drugs Market Share by Players (2016-2021)
  • Table 18. Global Top Follicular Lymphoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Follicular Lymphoma Drugs as of 2020)
  • Table 19. Ranking of Global Top Follicular Lymphoma Drugs Companies by Revenue (US$ Million) in 2020
  • Table 20. Global 5 Largest Players Market Share by Follicular Lymphoma Drugs Revenue (CR5 and HHI) & (2016-2021)
  • Table 21. Key Players Headquarters and Area Served
  • Table 22. Key Players Follicular Lymphoma Drugs Product Solution and Service
  • Table 23. Date of Enter into Follicular Lymphoma Drugs Market
  • Table 24. Mergers & Acquisitions, Expansion Plans
  • Table 25. Global Follicular Lymphoma Drugs Market Size by Type (2016-2021) (US$ Million)
  • Table 26. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2016-2021)
  • Table 27. Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
  • Table 28. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
  • Table 29. Global Follicular Lymphoma Drugs Market Size Share by Administration Route (2016-2021) & (US$ Million)
  • Table 30. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2016-2021)
  • Table 31. Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2022-2027) (US$ Million)
  • Table 32. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2022-2027) & (US$ Million)
  • Table 33. North America Follicular Lymphoma Drugs Market Size by Type (2016-2021) (US$ Million)
  • Table 34. North America Follicular Lymphoma Drugs Market Size by Type (2022-2027) & (US$ Million)
  • Table 35. North America Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021) (US$ Million)
  • Table 36. North America Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027) & (US$ Million)
  • Table 37. North America Follicular Lymphoma Drugs Market Size by Country (2016-2021) & (US$ Million)
  • Table 38. North America Follicular Lymphoma Drugs Market Size by Country (2022-2027) & (US$ Million)
  • Table 39. Europe Follicular Lymphoma Drugs Market Size by Type (2016-2021) (US$ Million)
  • Table 40. Europe Follicular Lymphoma Drugs Market Size by Type (2022-2027) & (US$ Million)
  • Table 41. Europe Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021) (US$ Million)
  • Table 42. Europe Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027) & (US$ Million)
  • Table 43. Europe Follicular Lymphoma Drugs Market Size by Country (2016-2021) & (US$ Million)
  • Table 44. Europe Follicular Lymphoma Drugs Market Size by Country (2022-2027) & (US$ Million)
  • Table 45. Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2016-2021) (US$ Million)
  • Table 46. Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2022-2027) & (US$ Million)
  • Table 47. Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021) (US$ Million)
  • Table 48. Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027) & (US$ Million)
  • Table 49. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2016-2021) & (US$ Million)
  • Table 50. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2022-2027) & (US$ Million)
  • Table 51. Latin America Follicular Lymphoma Drugs Market Size by Type (2016-2021) (US$ Million)
  • Table 52. Latin America Follicular Lymphoma Drugs Market Size by Type (2022-2027) & (US$ Million)
  • Table 53. Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021) (US$ Million)
  • Table 54. Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027) & (US$ Million)
  • Table 55. Latin America Follicular Lymphoma Drugs Market Size by Country (2016-2021) & (US$ Million)
  • Table 56. Latin America Follicular Lymphoma Drugs Market Size by Country (2022-2027) & (US$ Million)
  • Table 57. Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2016-2021) (US$ Million)
  • Table 58. Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2022-2027) & (US$ Million)
  • Table 59. Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021) (US$ Million)
  • Table 60. Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027) & (US$ Million)
  • Table 61. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2016-2021) & (US$ Million)
  • Table 62. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2022-2027) & (US$ Million)
  • Table 63. Roche Company Details
  • Table 64. Roche Business Overview
  • Table 65. Roche Follicular Lymphoma Drugs Product
  • Table 66. Roche Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 67. Roche Recent Development
  • Table 68. Gilead Sciences Company Details
  • Table 69. Gilead Sciences Business Overview
  • Table 70. Gilead Sciences Follicular Lymphoma Drugs Product
  • Table 71. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 72. Gilead Sciences Recent Development
  • Table 73. TG Therapeutics Company Details
  • Table 74. TG Therapeutics Business Overview
  • Table 75. TG Therapeutics Follicular Lymphoma Drugs Product
  • Table 76. TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 77. TG Therapeutics Recent Development
  • Table 78. Bayer Company Details
  • Table 79. Bayer Business Overview
  • Table 80. Bayer Follicular Lymphoma Drugs Product
  • Table 81. Bayer Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 82. Bayer Recent Development
  • Table 83. Secura Bio Company Details
  • Table 84. Secura Bio Business Overview
  • Table 85. Secura Bio Follicular Lymphoma Drugs Product
  • Table 86. Secura Bio Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 87. Secura Bio Recent Development
  • Table 88. Epizyme Company Details
  • Table 89. Epizyme Business Overview
  • Table 90. Epizyme Follicular Lymphoma Drugs Product
  • Table 91. Epizyme Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 92. Epizyme Recent Development
  • Table 93. Eisai Company Details
  • Table 94. Eisai Business Overview
  • Table 95. Eisai Follicular Lymphoma Drugs Product
  • Table 96. Eisai Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 97. Eisai Recent Development
  • Table 98. Acrotech Biopharma Company Details
  • Table 99. Acrotech Biopharma Business Overview
  • Table 100. Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 101. Acrotech Biopharma Recent Development
  • Table 102. Teva Company Details
  • Table 103. Teva Business Overview
  • Table 104. Teva Follicular Lymphoma Drugs Product
  • Table 105. Teva Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 106. Teva Recent Development
  • Table 107. Eagle Pharmaceuticals Company Details
  • Table 108. Eagle Pharmaceuticals Business Overview
  • Table 109. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product
  • Table 110. Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 111. Eagle Pharmaceuticals Recent Development
  • Table 112. MundiPharma Company Details
  • Table 113. MundiPharma Business Overview
  • Table 114. MundiPharma Follicular Lymphoma Drugs Product
  • Table 115. MundiPharma Revenue in Follicular Lymphoma Drugs Business (2016-2021) & (US$ Million)
  • Table 116. MundiPharma Recent Development
  • Table 117. Research Programs/Design for This Report
  • Table 118. Key Data Information from Secondary Sources
  • Table 119. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Follicular Lymphoma Drugs Market Share by Type: 2020 VS 2027
  • Figure 2. Anti-CD20 mAbs Features
  • Figure 3. Chemotherapy Agents Features
  • Figure 4. Kinase Inhibitor Features
  • Figure 5. Others Features
  • Figure 6. Global Follicular Lymphoma Drugs Market Share by Administration Route: 2020 VS 2027
  • Figure 7. Injection Case Studies
  • Figure 8. Oral Case Studies
  • Figure 9. Follicular Lymphoma Drugs Report Years Considered
  • Figure 10. Global Follicular Lymphoma Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
  • Figure 11. Global Follicular Lymphoma Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
  • Figure 12. Global Follicular Lymphoma Drugs Market Share by Regions: 2020 VS 2027
  • Figure 13. Global Follicular Lymphoma Drugs Market Share by Regions (2022-2027)
  • Figure 14. Global Follicular Lymphoma Drugs Market Share by Players in 2020
  • Figure 15. Global Top Follicular Lymphoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Follicular Lymphoma Drugs as of 2020
  • Figure 16. The Top 10 and 5 Players Market Share by Follicular Lymphoma Drugs Revenue in 2020
  • Figure 17. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2016-2021)
  • Figure 18. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2022-2027)
  • Figure 19. North America Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 20. North America Follicular Lymphoma Drugs Market Share by Type (2016-2027)
  • Figure 21. North America Follicular Lymphoma Drugs Market Share by Administration Route (2016-2027)
  • Figure 22. North America Follicular Lymphoma Drugs Market Share by Country (2016-2027)
  • Figure 23. United States Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 24. Canada Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 25. Europe Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 26. Europe Follicular Lymphoma Drugs Market Share by Type (2016-2027)
  • Figure 27. Europe Follicular Lymphoma Drugs Market Share by Administration Route (2016-2027)
  • Figure 28. Europe Follicular Lymphoma Drugs Market Share by Country (2016-2027)
  • Figure 29. Germany Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 30. France Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 31. U.K. Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 32. Italy Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 33. Russia Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 34. Nordic Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 35. Asia-Pacific Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 36. Asia-Pacific Follicular Lymphoma Drugs Market Share by Type (2016-2027)
  • Figure 37. Asia-Pacific Follicular Lymphoma Drugs Market Share by Administration Route (2016-2027)
  • Figure 38. Asia-Pacific Follicular Lymphoma Drugs Market Share by Region (2016-2027)
  • Figure 39. China Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 40. Japan Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 41. South Korea Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 42. Southeast Asia Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 43. India Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 44. Australia Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 45. Latin America Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 46. Latin America Follicular Lymphoma Drugs Market Share by Type (2016-2027)
  • Figure 47. Latin America Follicular Lymphoma Drugs Market Share by Administration Route (2016-2027)
  • Figure 48. Latin America Follicular Lymphoma Drugs Market Share by Country (2016-2027)
  • Figure 49. Mexico Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 50. Brazil Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 51. Middle East & Africa Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 52. Middle East & Africa Follicular Lymphoma Drugs Market Share by Type (2016-2027)
  • Figure 53. Middle East & Africa Follicular Lymphoma Drugs Market Share by Administration Route (2016-2027)
  • Figure 54. Middle East & Africa Follicular Lymphoma Drugs Market Share by Country (2016-2027)
  • Figure 55. Turkey Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 56. Saudi Arabia Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 57. UAE Follicular Lymphoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
  • Figure 58. Roche Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 59. Gilead Sciences Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 60. TG Therapeutics Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 61. Bayer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 62. Secura Bio Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 63. Epizyme Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 64. Eisai Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 65. Acrotech Biopharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 66. Teva Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 67. Eagle Pharmaceuticals Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 68. MundiPharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2016-2021)
  • Figure 69. Bottom-up and Top-down Approaches for This Report
  • Figure 70. Data Triangulation
  • Figure 71. Key Executives Interviewed
目次

Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.

Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.

Market Analysis and Insights: Global Follicular Lymphoma Drugs Market

The global Follicular Lymphoma Drugs market size is projected to reach US$ 2620.1 million by 2027, from US$ 1616 million in 2020, at a CAGR of 7.4% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Follicular Lymphoma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Follicular Lymphoma Drugs market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Follicular Lymphoma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Follicular Lymphoma Drugs market.

Global Follicular Lymphoma Drugs Scope and Market Size

Follicular Lymphoma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Follicular Lymphoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Administration Route in terms of revenue and forecast for the period 2016-2027.

Segment by Type

  • Anti-CD20 mAbs
  • Chemotherapy Agents
  • Kinase Inhibitor
  • Others

Segment by Administration Route

  • Injection
  • Oral

By Region

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Nordic
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

By Company

  • Roche
  • Gilead Sciences
  • TG Therapeutics
  • Bayer
  • Secura Bio
  • Epizyme
  • Eisai
  • Acrotech Biopharma
  • Teva
  • Eagle Pharmaceuticals
  • MundiPharma

TABLE OF CONTENTS

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Anti-CD20 mAbs
    • 1.2.3 Chemotherapy Agents
    • 1.2.4 Kinase Inhibitor
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global Follicular Lymphoma Drugs Market Share by Administration Route: 2016 VS 2021 VS 2027
    • 1.3.2 Injection
    • 1.3.3 Oral
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Follicular Lymphoma Drugs Market Perspective (2016-2027)
  • 2.2 Follicular Lymphoma Drugs Growth Trends by Regions
    • 2.2.1 Follicular Lymphoma Drugs Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Follicular Lymphoma Drugs Historic Market Share by Regions (2016-2021)
    • 2.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Regions (2022-2027)
  • 2.3 Follicular Lymphoma Drugs Industry Dynamic
    • 2.3.1 Follicular Lymphoma Drugs Market Trends
    • 2.3.2 Follicular Lymphoma Drugs Market Drivers
    • 2.3.3 Follicular Lymphoma Drugs Market Challenges
    • 2.3.4 Follicular Lymphoma Drugs Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Follicular Lymphoma Drugs Players by Revenue
    • 3.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2016-2021)
    • 3.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2016-2021)
  • 3.2 Global Follicular Lymphoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Follicular Lymphoma Drugs Revenue
  • 3.4 Global Follicular Lymphoma Drugs Market Concentration Ratio
    • 3.4.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Drugs Revenue in 2020
  • 3.5 Follicular Lymphoma Drugs Key Players Head office and Area Served
  • 3.6 Key Players Follicular Lymphoma Drugs Product Solution and Service
  • 3.7 Date of Enter into Follicular Lymphoma Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Follicular Lymphoma Drugs Breakdown Data by Type

  • 4.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2016-2021)
  • 4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2022-2027)

5 Follicular Lymphoma Drugs Breakdown Data by Administration Route

  • 5.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2016-2021)
  • 5.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2022-2027)

6 North America

  • 6.1 North America Follicular Lymphoma Drugs Market Size (2016-2027)
  • 6.2 North America Follicular Lymphoma Drugs Market Size by Type
    • 6.2.1 North America Follicular Lymphoma Drugs Market Size by Type (2016-2021)
    • 6.2.2 North America Follicular Lymphoma Drugs Market Size by Type (2022-2027)
    • 6.2.3 North America Follicular Lymphoma Drugs Market Size by Type (2016-2027)
  • 6.3 North America Follicular Lymphoma Drugs Market Size by Administration Route
    • 6.3.1 North America Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021)
    • 6.3.2 North America Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027)
    • 6.3.3 North America Follicular Lymphoma Drugs Market Size by Administration Route (2016-2027)
  • 6.4 North America Follicular Lymphoma Drugs Market Size by Country
    • 6.4.1 North America Follicular Lymphoma Drugs Market Size by Country (2016-2021)
    • 6.4.2 North America Follicular Lymphoma Drugs Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Follicular Lymphoma Drugs Market Size (2016-2027)
  • 7.2 Europe Follicular Lymphoma Drugs Market Size by Type
    • 7.2.1 Europe Follicular Lymphoma Drugs Market Size by Type (2016-2021)
    • 7.2.2 Europe Follicular Lymphoma Drugs Market Size by Type (2022-2027)
    • 7.2.3 Europe Follicular Lymphoma Drugs Market Size by Type (2016-2027)
  • 7.3 Europe Follicular Lymphoma Drugs Market Size by Administration Route
    • 7.3.1 Europe Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021)
    • 7.3.2 Europe Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027)
    • 7.3.3 Europe Follicular Lymphoma Drugs Market Size by Administration Route (2016-2027)
  • 7.4 Europe Follicular Lymphoma Drugs Market Size by Country
    • 7.4.1 Europe Follicular Lymphoma Drugs Market Size by Country (2016-2021)
    • 7.4.2 Europe Follicular Lymphoma Drugs Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2016-2027)
  • 8.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type
    • 8.2.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route
    • 8.3.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021)
    • 8.3.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027)
    • 8.3.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Administration Route (2016-2027)
  • 8.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region
    • 8.4.1 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Follicular Lymphoma Drugs Market Size (2016-2027)
  • 9.2 Latin America Follicular Lymphoma Drugs Market Size by Type
    • 9.2.1 Latin America Follicular Lymphoma Drugs Market Size by Type (2016-2021)
    • 9.2.2 Latin America Follicular Lymphoma Drugs Market Size by Type (2022-2027)
    • 9.2.3 Latin America Follicular Lymphoma Drugs Market Size by Type (2016-2027)
  • 9.3 Latin America Follicular Lymphoma Drugs Market Size by Administration Route
    • 9.3.1 Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021)
    • 9.3.2 Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027)
    • 9.3.3 Latin America Follicular Lymphoma Drugs Market Size by Administration Route (2016-2027)
  • 9.4 Latin America Follicular Lymphoma Drugs Market Size by Country
    • 9.4.1 Latin America Follicular Lymphoma Drugs Market Size by Country (2016-2021)
    • 9.4.2 Latin America Follicular Lymphoma Drugs Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2016-2027)
  • 10.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type
    • 10.2.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route
    • 10.3.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2016-2021)
    • 10.3.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2022-2027)
    • 10.3.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Administration Route (2016-2027)
  • 10.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country
    • 10.4.1 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Roche
    • 11.1.1 Roche Company Details
    • 11.1.2 Roche Business Overview
    • 11.1.3 Roche Follicular Lymphoma Drugs Introduction
    • 11.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.1.5 Roche Recent Development
  • 11.2 Gilead Sciences
    • 11.2.1 Gilead Sciences Company Details
    • 11.2.2 Gilead Sciences Business Overview
    • 11.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction
    • 11.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.2.5 Gilead Sciences Recent Development
  • 11.3 TG Therapeutics
    • 11.3.1 TG Therapeutics Company Details
    • 11.3.2 TG Therapeutics Business Overview
    • 11.3.3 TG Therapeutics Follicular Lymphoma Drugs Introduction
    • 11.3.4 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.3.5 TG Therapeutics Recent Development
  • 11.4 Bayer
    • 11.4.1 Bayer Company Details
    • 11.4.2 Bayer Business Overview
    • 11.4.3 Bayer Follicular Lymphoma Drugs Introduction
    • 11.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.4.5 Bayer Recent Development
  • 11.5 Secura Bio
    • 11.5.1 Secura Bio Company Details
    • 11.5.2 Secura Bio Business Overview
    • 11.5.3 Secura Bio Follicular Lymphoma Drugs Introduction
    • 11.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.5.5 Secura Bio Recent Development
  • 11.6 Epizyme
    • 11.6.1 Epizyme Company Details
    • 11.6.2 Epizyme Business Overview
    • 11.6.3 Epizyme Follicular Lymphoma Drugs Introduction
    • 11.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.6.5 Epizyme Recent Development
  • 11.7 Eisai
    • 11.7.1 Eisai Company Details
    • 11.7.2 Eisai Business Overview
    • 11.7.3 Eisai Follicular Lymphoma Drugs Introduction
    • 11.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.7.5 Eisai Recent Development
  • 11.8 Acrotech Biopharma
    • 11.8.1 Acrotech Biopharma Company Details
    • 11.8.2 Acrotech Biopharma Business Overview
    • 11.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction
    • 11.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.8.5 Acrotech Biopharma Recent Development
  • 11.9 Teva
    • 11.9.1 Teva Company Details
    • 11.9.2 Teva Business Overview
    • 11.9.3 Teva Follicular Lymphoma Drugs Introduction
    • 11.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.9.5 Teva Recent Development
  • 11.10 Eagle Pharmaceuticals
    • 11.10.1 Eagle Pharmaceuticals Company Details
    • 11.10.2 Eagle Pharmaceuticals Business Overview
    • 11.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction
    • 11.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.10.5 Eagle Pharmaceuticals Recent Development
  • 11.11 MundiPharma
    • 11.11.1 MundiPharma Company Details
    • 11.11.2 MundiPharma Business Overview
    • 11.11.3 MundiPharma Follicular Lymphoma Drugs Introduction
    • 11.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2016-2021)
    • 11.11.5 MundiPharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Disclaimer
  • 13.3 Author Details